Angiotensin converting enzyme 2: A new important player in the regulation of glycemia

IUBMB Life

Volumn 65, Issue 9, 2013, Pages 731-738

  Chhabra, Kavaljit H ^a   Chodavarapu, Harshita ^a   Lazartigues, Eric ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A disintegrin, and metalloproteinase (ADAM17); angiotensin (1 7); angiotensin converting enyzme 2; MasR; Type 2 diabetes

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN CONVERTING ENZYME 2; DIMINAZENE ACETURATE; DISINTEGRIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR SUBSTRATE 1; IRBESARTAN; LENTIVIRUS VECTOR; METALLOPROTEINASE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; OLMESARTAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; VALSARTAN;

ADIPOSE TISSUE; BLOOD FLOW; CAROTID ATHEROSCLEROSIS; DIABETIC PATIENT; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GENE THERAPY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET; PREGNANCY DIABETES MELLITUS; PROTEIN EXPRESSION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR SMOOTH MUSCLE;

ANIMALIA; MUS;

A DISINTEGRIN, AND METALLOPROTEINASE (ADAM17); ANGIOTENSIN (1-7); ANGIOTENSIN CONVERTING ENYZME 2; MASR; TYPE 2 DIABETES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 84883258979     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1190     Document Type: Review

References (89)

1. Bindom, S. M., Hans, C. P., Xia, H., Boulares, A. H., and, Lazartigues, E., (2010) Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59, 2540-2548.
2. Takeda, M., Yamamoto, K., Takemura, Y., Takeshita, H., Hongyo, K., et al. (2012) Loss of ACE 2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes 62, 223-233.
3. Niu, M.-J., Yang, J.-K., Lin, S.-S., Ji, X.-J., and, Guo, L.-M., (2008) Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 34, 56-61.
4. Bindom, S. M., and, Lazartigues, E., (2009) The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol. 302, 193-202.
5. Lau, T, Carlsson, P. O., and, Leung, P. S., (2004) Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47, 240-248.
6. Saiki, A., Ohira, M., Endo, K., Koide, N., Oyama, T., et al. (2009) Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 58, 708-713.
7. Ogihara, T., Asano, T., Ando, K., Chiba, Y., Sakoda, H., et al. (2002) Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40, 872-879.
8. Carlsson, P. O., Berne, C., and, Jansson, L., (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41, 127-133.
9. Luther, J. M., and, Brown, N. J., (2011) The renin-angiotensin- aldosterone system and glucose homeostasis. Trends Pharmacol. Sci. 32, 734-739.
10. Tocci, G., Paneni, F., Palano, F., Sciarretta, S., Ferrucci, A., et al. (2011) Angiotensin-converting enzyme inhibitors, Angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am. J. Hypertens. 24, 582-590.
11. Abuissa, H., Jones, P. G., Marso, S. P., and, O'Keefe, J. H. Jr,. (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46, 821-826.
12. Wagner, J., Jan Danser, A. H., Derkx, F. H., de Jong, T. V., Paul, M., et al. (1996) Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br. J. Ophthalmol. 80, 159-163.
13. McKinley, M. J., Albiston, A. L., Allen, A. M., Mathai, M. L., May, C. N., et al. (2003) The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 35, 901-918.
14. Serneri, G. G. N., Boddi, M., Coppo, M., Chechi, T., Zarone, N., et al. (1996) Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 94, 1886-1893.
15. Caldwell, P. R., Seegal, B. C., Hsu, K. C., Das, M., and, Soffer, R. L., (1976) Angiotensin-converting enzyme: vascular endothelial localization. Science 191, 1050-1051.
16. Gunther, S., Gimbrone, M. A. Jr,., and, Alexander, R. W., (1980) Identification and characterization of the high affinity vascular angiotensin II receptor in rat mesenteric artery. Circ. Res. 47, 278-286.
17. Naftilan, A. J., Zuo, W. W., Inglefinger, J., Ryan, T. J. Jr,., Pratt, R. E., et al. (1991) Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J. Clin. Invest. 87, 1300-1311.
18. Leung, P. S., Chan, W. P., Wong, T. P., and, Sernia, C., (1999) Expression and localization of the renin-angiotensin system in the rat pancreas. J. Endocrinol. 160, 13-19.
19. Leung, P. S., Chan, H. C., Fu, L. X., and, Wong, P. Y., (1997) Localization of angiotensin II receptor subtypes AT1 and AT2 in the pancreas of rodents. J. Endocrinol. 153, 269-274.
20. Leung, P. S., Chan, H. C., and, Wong, P. Y., (1998) Immunohistochemical localization of angiotensin II in the mouse pancreas. Histochem. J. 30, 21-25.
21. Tahmasebi, M., Puddefoot, J. R., Inwang, E. R., and, Vinson, G. P., (1999) The tissue renin-angiotensin system in human pancreas. J. Endocrinol. 161, 317-322.
22. Folli, F., Kahn, C. R., Hansen, H., Bouchie, J. L., and, Feener, E. P., (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest. 100, 2158-2169.
23. Folli, F., Saad, M. J., Velloso, L., Hansen, H., Caradente, O., et al. (1999) Crosstalk between insulin and angiotensin II signalling systems. Exp. Clin. Endocrinol. Diab. 107, 133-139.
24. Mitsuishi, M., Miyashita, K., Muraki, A., and, Itoh, H., (2009) Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes 58, 710-717.
25. Henriksen, E. J., Jacob, S., Kinnick, T. R., Teachey, M. K., and, Krekler, M., (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38, 884-890.
26. Shiuchi, T., Iwai, M., Li, H.-S., Wu, L., Min, L.-J., et al. (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43, 1003-1010.
27. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., et al. (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1-E9.
28. Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., et al. (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238-33243.
29. Gembardt, F., Sterner-Kock, A., Imboden, H., Spalteholz, M., Reibitz, F., et al. (2005) Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26, 1270-1277.
30. Tikellis, C., Wookey, P. J., Candido, R., Andrikopoulos, S., Thomas, M. C., et al. (2004) Improved islet morphology after blockade of the renin-angiotensin system in the ZDF Rat. Diabetes 53, 989-997.
31. Bindom, S. M., Hans, C. P., Xia, H., Boulares, A. H., and, Lazartigues, E., (2010) Angiotensin-I converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59, 2540-2548.
32. Fang, H. J., and, Yang, J. K., (2010) Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas. J. Int. Med. Res. 38, 558-569.
33. Paizis, G., Tikellis, C., Cooper, M. E., Schembri, J. M., Lew, R. A., et al. (2005) Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 54, 1790-1796.
34. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843.
35. Moriguchi, A., Tallant, E. A., Matsumura, K., Reilly, T. M., Walton, H., et al. (1995) Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 25, 1260-1265.
36. Santos, R. A. S., Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA 100, 8258-8263.
37. Feng, Y., Xia, H., Cai, Y., Halabi, C. M., Becker, L. K., et al. (2010) Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ. Res. 106, 373-382.
38. Xia, H., Feng, Y., Obr, T. D., Hickman, P. J., and, Lazartigues E., (2009) Angiotensin II type 1 receptor-mediated reduction of angiotensin- converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension 53, 210-216.
39. Shenoy, V., Ferreira, A. J., Qi, Y., Fraga-Silva, R. A., DÃez-Freire, C., et al. (2010) The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 182, 1065-1072.
40. Raizada, M. K., and, Ferreira, A. J., (2007) ACE2: a new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol. 50, 112-119.
41. Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828.
42. Yamazato, M., Yamazato, Y., Sun, C., Diez-Freire, C., and, Raizada, M. K., (2007) Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49, 926-931.
43. Chhabra, K. H., Xia, H., Pedersen, K. B., Speth, R. C., and, Lazartigues, E., (2013) Pancreatic angiotensin-converting enzyme 2 (ACE2) improves glycemia in angiotensin II-infused mice. Am. J. Physiol. Endocrinol. Metab. 304, E874-E884.
44. Ye, M., Wysocki, J., William, J., Soler, M. J., Cokic, I., et al. (2006) Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17, 3067-3075.
45. Oudit, G. Y., Liu, G. C., Zhong, J., Basu, R., Chow, F. L., et al. (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59, 529-538.
46. Verma, A., Shan, Z., Lei, B., Yuan, L., Liu, X., et al. (2012) ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol. Ther. 20, 28-36.
47. Xia, H., Suda, S., Bindom, S., Feng, Y., Gurley, S. B., et al. (2011) ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One 6, e22682.
48. Hitomi, H., Kiyomoto, H., and, Nishiyama, A., (2007) Angiotensin II and oxidative stress. Curr. Opin. Cardiol. 22, 311-315.
49. Yoshitaka, K., and, Hideaki, K., (2004) Role of oxidative stress in pancreatic β-cell dysfunction. Ann. N Y Acad. Sci. 1011, 168-176.
50. Gwathmey, T. M., Pendergrass, K. D., Reid, S. D., Rose, J. C., Diz, D. I., et al. (2010) Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension 55, 166-171.
51. Maritim, A. C., Sanders, R. A., and, Watkins, J. B. III,. (2003) Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24-38.
52. Carlsson, P. O., Andersson, A., and, Jansson, L., (1996) Pancreatic islet blood flow in normal and obese-hyperglycemic (ob/ob) mice. Am. J. Physiol. Endocrinol. Metab. 271, E990-E995.
53. Hayden, M. R., and, Sowers, J. R., (2007) Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid. Redox Signal. 9, 891-910.
54. Donath, M. Y., Marianne, B.-S., Ellingsgaard, H., and, Ehses, J. A., (2009) Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 24, 325-331.
55. Feng, Y., Hans, C., McIlwain, E., Varner, K. J., and, Lazartigues, E., (2012) Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. PLoS ONE 7, e48910.
56. Zhong, J., Basu, R., Guo, D., Chow, F. L., Byrns, S., et al. (2010) Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122, 717-728.
57. Österreicher, C. H., Taura, K., De Minicis, S., Seki, E., Penz-Österreicher, M., et al. (2009) Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology 50, 929-938.
58. Chodavarapu, H., Chhabra, K. H., Shenoy, V., Raizada, M. K., Yue, X., et al. (2013) ACE2 gene therapy decreases fibrosis in the pancreas of high fat diet-fed mice. FASEB J. 27, 1154.7.
59. Hayden, M., Karuparthi, P., Habibi, J., Waseker, C., Lastra, G., et al. (2007) Ultrastructural islet study of early fibrosis in the Ren2 model of hypertension. Emerging role of the islet pancreatic pericyte-stellate cell. JOP 8, 725-738.
60. Leung, P. S., (2007) The physiology of a local renin-angiotensin system in the pancreas. J. Physiol. 580, 31-37.
61. Young, C. N., Cao, X., Guruju, M. R., Pierce, J. P., Morgan, D. A., et al. (2012) ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension. J. Clin. Invest. 122, 3960-3964.
62. Flamment, M., Hajduch, E., Ferré, P., and, Foufelle, F., (2012) New insights into ER stress-induced insulin resistance. Trends Endocrinol. Metab. 23, 381-390.
63. Negi, S., Park, S. H., Jetha, A., Aikin, R., Tremblay, M., et al. (2012) Evidence of endoplasmic reticulum stress mediating cell death in transplanted human islets. Cell Transplant. 21, 889-900.
64. Reich, H. N., Oudit, G. Y., Penninger, J. M., Scholey, J. W., and, Herzenberg, A. M., (2008) Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 74, 1610-1616.
65. Tikellis, C., Johnston, C. I., Forbes, J. M., Burns, W. C., Burrell, L. M., et al. (2003) Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41, 392-397.
66. Lambert, D. W., Yarski, M., Warner, F. J., Thornhill, P., Parkin, E.T., et al. (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280, 30113-30119.
67. Cardellini, M., Menghini, R., Martelli, E., Casagrande, V., Marino, A., et al. (2009) TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 58, 2396-2401.
68. Ohtsu, H., Dempsey, P. J., Frank, G. D., Brailoiu, E., Higuchi, S., et al. (2006) ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 26, e133-e137.
69. Gupte, M., Boustany-Kari, C. M., Bharadwaj, K., Police, S., Thatcher, S., et al. (2008) ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am. Physiol. Regul. Integr. Comp. Physiol. 295, R781-R788.
70. Gupte, M., Thatcher, S. E., Boustany-Kari, C. M., Shoemaker, R., Yiannikouris, F., et al. (2012) Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler. Thromb. Vasc. Biol. 32, 1392-1399.
71. Chhabra, K. H., Pedersen, K. B., Xia, H., Shenoy, V., Raizada, M. K., et al. (2013) Pancreatic ACE2 shedding is associated with impaired glycemia in high fat diet-fed mice. FASEB J. 27, 1154.1.
72. Xia, H., Sriramula, S., Scroggin, M., Chhabra, K. H., and, Lazartigues, E., (2012) ACE2 shedding: a new mechanism for neurogenic hypertension. FASEB J. 26, 893.1.
73. Feng, Y., Yue, X., Xia, H., Bindom, S. M., Hickman, P. J., et al. (2008) Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ. Res. 102, 729-736.
74. Mecca, A. P., Regenhardt, R. W., O'Connor, T. E., Joseph, J. P., Raizada, M. K., et al. (2011) Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp. Physiol. 96, 1084-1096.
75. Jarajapu, Y. P. R., Bhatwadekar, A. D., Caballero, S., Hazra, S., Shenoy, V., et al. (2012) Activation of the ACE2/angiotensin-(1-7)/Mas Receptor Axis Enhances the Reparative Function of Dysfunctional Diabetic Endothelial Progenitors. Diabetes 62, 1258-1269.
76. Murca, T. M., Moraes, P. L., Capuruco, C. A. B., Santos, S. H. S., Melo, M. B., et al. (2012) Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul. Pept. 177, 107-115.
77. Park, S., Bivona, B. J., Ford, S. M., Xu, S., Kobori, H., et al. (2012) Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature. Hypertension 61, 465-471.
78. Iwai, M., Nakaoka, H., Senba, I., Kanno, H., Moritani, T., et al. (2012) Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodeling. Hypertension 60, 137-144.
79. Marcus, Y., Shefer, G., Sasson, K., Kohen, F., Limor, R., et al. (2012) Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes 62, 1121-1130.
80. Benter, I. F., Yousif, M. H. M., Dhaunsi, G. S., Kaur, J., Chappell, M. C., et al. (2008) Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 28, 25-33.
81. Munoz, M. C., Giani, J. F., Burghi, V., Mayer, M. A., Carranza, A., et al. (2012) The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7). Regul. Pept. 177, 1-11.
82. Giani, J. F., Mayer, M. A., Munoz, M. C., Silberman, E. A., Hocht, C., et al. (2009) Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am. J. Physiol. Endocrinol. Metab. 296, E262-E271.
83. Santos, S. H., Braga, J. F., Mario, E. G., Porto, L. C., Rodrigues-Machado Mda, G., et al. (2010) Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler. Thromb. Vasc. Biol. 30, 953-961.
84. Benter, I. F., Yousif, M. H. M., Cojocel, C., Al-Maghrebi, M., and, Diz, D. I., (2007) Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H666-H672.
85. Kohara, K., Brosnihan, K. B., and, Ferrario, C. M., (1993) Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 14, 883-891.
86. Nogueira, A. I., Souza Santos, R. A., Simões e Silva, A. C., Cabral, A. C. V., Vieira, R. L. P., et al. (2007) The pregnancy-induced increase of plasma angiotensin-(1-7) is blunted in gestational diabetes. Regul. Pept. 141, 55-60.
87. Xu, P., Costa-Goncalves, A. C., Todiras, M., Rabelo, L. A., Sampaio, W. O., et al. (2008) Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice. Hypertension 51, 574-580.
88. Santos, S. H., Fernandes, L. R., Mario, E. G., Ferreira, A. V., Pôrto, L. C., et al. (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57, 340-347.
89. Ebermann, L., Spillmann, F., Sidiropoulos, M., Escher, F., Heringer-Walther, S., et al. (2008) The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur. J. Pharmacol. 590, 276-280.